Breakthrough Agents Reshaping RRMM Treatment Landscape

Opinion
Video

Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content
Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy
March 4th 2024
Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.